FDA Approves First siRNA Therapy for Myasthenia Gravis
Source Summary
The FDA has approved cemdisiran (Livsayis), a subcutaneous siRNA therapy developed by Regeneron, for treating generalized myasthenia gravis in adults with anti-acetylcholine receptor antibody positivity. This marks the first siRNA therapy approved for this autoimmune neuromuscular disorder.
Why it matters
This approval introduces a novel RNA-based mechanism to treat a rare autoimmune disorder previously managed only with conventional immunosuppressive and symptomatic therapies.



